- Home
- LSF vs DTIL Comparison
LSF vs DTIL Comparison
Compare LSF & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | DTIL |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 123.0M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LSF | DTIL |
|---|---|---|
| Price | $2.11 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $47.00 |
| AVG Volume (30 Days) | 95.9K | ★ 198.7K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $698,000.00 |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.07 | $3.61 |
| 52 Week High | $8.96 | $8.82 |
Technical Indicators
Market Signals| Indicator | LSF | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 42.80 |
| Support Level | $2.13 | $4.61 |
| Resistance Level | $2.52 | $5.20 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 0.65 | 41.08 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.